Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT04912960
Recruiting Observational

PEEP in Patients With Acute Respiratory Failure

NCT04912960 · tracked via the Priya Life Science Spain tracker
Sponsor
Jesus Villar
Phase
Observational
Started
2021-06-10
Last updated
2025-04-20

Condition(s) studied

Acute Respiratory Failure With Hypoxia

Investigational drug(s) / intervention(s)

Mechanical ventilation

Mechanical ventilation: Optimum PEEP

Study summary

Positive end-expiratory pressure (PEEP) has become an essential component of the care of critically ill patients who require ventilatory support. In 1975, several investigators published the effects of PEEP in 15 mechanically ventilated patients with acute respiratory failure (ARF) supported by mechanical ventilation. FiO2 ranged between 21% to 75% and the tidal volume between 13 to 15 mL/kg. PEEP was increased in 3 cmH2O steps until cardiac output fell. The aim was to identify the "optimum" PEEP level. "Best" PEEP was associated simultaneously with the best static compliance of the respiratory system, the greatest oxygen transport, and the lowest dead space fraction. That study established the basis for the use of PEEP in patients with ARF worldwide. Although currently patients with ARF are ventilated with much lower tidal volumes, that study has never been validated. It is unknow whether their findings are currently valid, generalizable, and reproducible.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Intubated patients requiring MV for \>24 h * Age \>18 years * Acute hypoxemic respiratory failure, defined as a PaO2/FiO2 \<300 with an FiO2 ≥0.3 and PEEP≥5 cmH2O. * ARF caused by pulmonary insults. Exclusion Criteria: * ARF from non-pulmonary origin. * Contraindications from high PEEP (severe head trauma or severe chest trauma). * Patients that cannot maintained supine position. * Uncorrected hypovolemia * Hemodynamic instability

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Hospital Universitario Dr. Negrin Las Palmas de Gran Canaria Las Palmas Recruiting
Hospital Clinic Barcelona Spain Not Yet Recruiting
Hospital Universitario La Princesa Madrid Spain Not Yet Recruiting

More Jesus Villar trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04912960 on ClinicalTrials.gov ↗ ← All trials in Spain